Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
Emerging treatment options for metabolic dysfunction-associated steatotic liver disease and its related liver diseases
Chun-Ye Zhang, Bond Life Sciences Center, University of Missouri, Columbia, MO 65212, United States
Ming Yang, Department of Surgery, School of Medicine, University of Connecticut, Far
Author contributions: Zhang CY and Yang M designed, wrote, revised, and finalized the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Ming Yang, PhD, Assistant Professor, Department of Surgery, School of Medicine, University of Connecticut, 263 Farmington Avenue, Farmington, CT 06030, United States. minyang@uchc.edu
Received: February 24, 2026
Revised: March 31, 2026
Accepted: April 17, 2026
Published online: June 27, 2026
Processing time: 124 Days and 7.7 Hours
Revised: March 31, 2026
Accepted: April 17, 2026
Published online: June 27, 2026
Processing time: 124 Days and 7.7 Hours
Core Tip
Core Tip: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common type of chronic liver disease, affecting more than a quarter of the global population. MASLD is driven by many factors, including dietary and genetic factors. Without effective treatment, MASLD can lead to liver cirrhosis and cancer. Currently, treatment options for MASLD and metabolic dysfunction-associated steatohepatitis (MASH), an advanced form of MASLD, are limited. Ongoing clinical trials suggest that drug repurposing for metabolic disorders, dietary modifications, exercise, natural products, and combination therapies offer promising strategies for the management and treatment of MASLD and MASH.